AU2016220096B2 - Phenothiazine analogues as mitochondrial therapeutic agents - Google Patents

Phenothiazine analogues as mitochondrial therapeutic agents Download PDF

Info

Publication number
AU2016220096B2
AU2016220096B2 AU2016220096A AU2016220096A AU2016220096B2 AU 2016220096 B2 AU2016220096 B2 AU 2016220096B2 AU 2016220096 A AU2016220096 A AU 2016220096A AU 2016220096 A AU2016220096 A AU 2016220096A AU 2016220096 B2 AU2016220096 B2 AU 2016220096B2
Authority
AU
Australia
Prior art keywords
therapeutic agents
mitochondrial
phenothiazine
analogues
phenothiazine analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016220096A
Other languages
English (en)
Other versions
AU2016220096A1 (en
Inventor
Indrajit BANDYOPADHAY
Sandipan Roy Chowdhury
Sidney Hecht
Omar Khdour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University Downtown Phoenix campus
Original Assignee
Arizona State University ASU
Arizona State University Downtown Phoenix campus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University ASU, Arizona State University Downtown Phoenix campus filed Critical Arizona State University ASU
Publication of AU2016220096A1 publication Critical patent/AU2016220096A1/en
Application granted granted Critical
Publication of AU2016220096B2 publication Critical patent/AU2016220096B2/en
Priority to AU2020202836A priority Critical patent/AU2020202836B2/en
Priority to AU2021201137A priority patent/AU2021201137A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016220096A 2015-02-17 2016-02-17 Phenothiazine analogues as mitochondrial therapeutic agents Active AU2016220096B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020202836A AU2020202836B2 (en) 2015-02-17 2020-04-29 Phenothiazine analogues as mitochondrial therapeutic agents
AU2021201137A AU2021201137A1 (en) 2015-02-17 2021-02-22 Phenothiazine analogues as mitochondrial therapeutic agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117205P 2015-02-17 2015-02-17
US62/117,205 2015-02-17
PCT/US2016/018233 WO2016133995A1 (en) 2015-02-17 2016-02-17 Phenothiazine analogues as mitochondrial therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202836A Division AU2020202836B2 (en) 2015-02-17 2020-04-29 Phenothiazine analogues as mitochondrial therapeutic agents

Publications (2)

Publication Number Publication Date
AU2016220096A1 AU2016220096A1 (en) 2017-08-31
AU2016220096B2 true AU2016220096B2 (en) 2020-01-30

Family

ID=56692740

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016220096A Active AU2016220096B2 (en) 2015-02-17 2016-02-17 Phenothiazine analogues as mitochondrial therapeutic agents
AU2020202836A Ceased AU2020202836B2 (en) 2015-02-17 2020-04-29 Phenothiazine analogues as mitochondrial therapeutic agents
AU2021201137A Abandoned AU2021201137A1 (en) 2015-02-17 2021-02-22 Phenothiazine analogues as mitochondrial therapeutic agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020202836A Ceased AU2020202836B2 (en) 2015-02-17 2020-04-29 Phenothiazine analogues as mitochondrial therapeutic agents
AU2021201137A Abandoned AU2021201137A1 (en) 2015-02-17 2021-02-22 Phenothiazine analogues as mitochondrial therapeutic agents

Country Status (7)

Country Link
US (3) US10472340B2 (https=)
EP (1) EP3258938B1 (https=)
JP (3) JP6807337B2 (https=)
AU (3) AU2016220096B2 (https=)
CA (1) CA2976776C (https=)
DK (1) DK3258938T3 (https=)
WO (1) WO2016133995A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016133995A1 (en) 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
US10364227B2 (en) 2015-02-17 2019-07-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10604501B2 (en) 2016-06-15 2020-03-31 Arizona Board Of Regents On Behalf Of Arizona State University Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
WO2018039487A1 (en) 2016-08-25 2018-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US12570622B2 (en) 2016-08-25 2026-03-10 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2018129411A1 (en) * 2017-01-06 2018-07-12 Bioelectron Technology Corporation Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders
FR3063495B1 (fr) * 2017-03-02 2019-04-05 Provepharm Life Solutions Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium
CN108484527B (zh) * 2018-04-27 2022-01-14 成都恒昊创新科技有限公司 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
DK3826639T3 (da) * 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
US12110313B2 (en) 2019-02-28 2024-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Engineered bacterial ribosome compositions and methods
WO2022171265A1 (en) * 2021-02-09 2022-08-18 Boehringer Ingelheim International Gmbh Modulators of complex i
CN119504646A (zh) * 2024-11-07 2025-02-25 长春工业大学 新型含有吩噻嗪结构药物小分子的合成及抗肿瘤活性研究

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338180A (en) * 1979-11-28 1982-07-06 Kuraray Co., Ltd. Photoelectrodes for photoelectrochemical cells
US20080062838A1 (en) * 2002-06-17 2008-03-13 Verification Technologies, Inc. Materials for optical medium copy-protection transiently reacting to a reader beam
US20130224634A1 (en) * 2010-11-08 2013-08-29 Bayer Intellectual Property Gmbh Photopolymer formulation for producing holographic media having highly crosslinked matrix polymers
US8759336B2 (en) * 2011-03-17 2014-06-24 Prosetta Antiviral Inc. Antiviral compounds
US20140275045A1 (en) * 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476722A (en) 1966-08-15 1969-11-04 Goodrich Co B F Process for polymerizing acrylic acid esters
DE2315349A1 (de) 1973-03-28 1974-10-03 Bayer Ag Nicht verfaerbende alterungsschutzmittel
JPS5168569A (en) 1974-12-10 1976-06-14 Fuji Photo Film Co Ltd 2 2 44 torimechiru 66 hidorokishi 77 chikankuromanruino seizoho
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5220042A (en) 1984-01-26 1993-06-15 Otsuka Pharmaceutical Co., Ltd. 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CA2099868C (en) 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
WO1996031217A1 (en) 1995-04-04 1996-10-10 Duke University Inhibiting retroviral replication
JP2001209176A (ja) 1999-04-02 2001-08-03 Fuji Photo Film Co Ltd 光重合性組成物およびそれを用いた記録材料
JP4064671B2 (ja) 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
WO2002000683A2 (en) 2000-06-23 2002-01-03 Vanderbilt University Novel chain-breaking antioxidants
AU2002319583B2 (en) 2001-07-20 2005-08-25 Eli Lilly And Company (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators
CA2505603A1 (en) 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
US20060188866A1 (en) 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
EP1863796A1 (en) 2005-03-22 2007-12-12 NeuroSearch A/S Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
US8268849B2 (en) 2007-09-25 2012-09-18 Board Of Regents Of The University Of Nebraska Multifunctional Antioxidants and methods of use thereof
EP2268311A4 (en) 2008-04-04 2014-08-27 Immunolight Llc NON-INVASIVE SYSTEMS AND IN SITU PHOTOBIOMODULATION METHODS
US8389583B2 (en) 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
ES2687177T3 (es) 2010-02-19 2018-10-24 Arizona Board Of Regents, A body corporate of the State of Arizona acting, For and on behalf of Arizona State University Inhibidores de radicales multifuncionales y su uso
CN102958525B (zh) * 2010-04-30 2017-05-24 普罗瑟塔抗病毒股份有限公司 抗病毒化合物
WO2012022467A2 (en) 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
CA2830581A1 (en) 2011-04-04 2012-10-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
KR101270160B1 (ko) 2011-05-16 2013-05-31 아주대학교산학협력단 가변색 이광자 형광프로브, 이를 이용한 미토콘드리아 내 티올 활성의 영상화 방법 및 이의 제조방법
US9440967B2 (en) 2012-02-10 2016-09-13 Arizona Board Of Regents On Behalf Of Arizona State University 1H-pyrrolo [2, 3 -B] pyridine derivatives and their use as radical quenchers
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
US9334250B2 (en) 2012-10-03 2016-05-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
JP2016501832A (ja) 2012-10-10 2016-01-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 多機能ラジカル消光剤
US10364227B2 (en) 2015-02-17 2019-07-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016133995A1 (en) 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
US10604501B2 (en) 2016-06-15 2020-03-31 Arizona Board Of Regents On Behalf Of Arizona State University Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
WO2018039487A1 (en) 2016-08-25 2018-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338180A (en) * 1979-11-28 1982-07-06 Kuraray Co., Ltd. Photoelectrodes for photoelectrochemical cells
US20080062838A1 (en) * 2002-06-17 2008-03-13 Verification Technologies, Inc. Materials for optical medium copy-protection transiently reacting to a reader beam
US20130224634A1 (en) * 2010-11-08 2013-08-29 Bayer Intellectual Property Gmbh Photopolymer formulation for producing holographic media having highly crosslinked matrix polymers
US8759336B2 (en) * 2011-03-17 2014-06-24 Prosetta Antiviral Inc. Antiviral compounds
US20140275045A1 (en) * 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders

Also Published As

Publication number Publication date
JP7113055B2 (ja) 2022-08-04
EP3258938B1 (en) 2020-12-02
JP6807337B2 (ja) 2021-01-06
WO2016133995A1 (en) 2016-08-25
JP2018505228A (ja) 2018-02-22
US11034662B2 (en) 2021-06-15
US10472340B2 (en) 2019-11-12
US20200115355A1 (en) 2020-04-16
JP2021006573A (ja) 2021-01-21
AU2016220096A1 (en) 2017-08-31
CA2976776C (en) 2023-06-20
US20220081404A1 (en) 2022-03-17
EP3258938A4 (en) 2018-10-31
US20180065941A1 (en) 2018-03-08
DK3258938T3 (da) 2021-02-01
CA2976776A1 (en) 2016-08-25
JP2022141896A (ja) 2022-09-29
AU2020202836B2 (en) 2020-12-17
AU2021201137A1 (en) 2021-03-11
EP3258938A1 (en) 2017-12-27
AU2020202836A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
AU2016220096B2 (en) Phenothiazine analogues as mitochondrial therapeutic agents
SG10201912416QA (en) Therapeutic agents
EP3199628A4 (en) Cytotoxicity-inducing therapeutic agent
GB201511790D0 (en) Pharmaceutical compound
EP3253382A4 (en) Pharmaceutical compositions for combination therapy
GB201509893D0 (en) Therapeutic agents
PL4233846T3 (pl) Formulacje farmaceutyczne
IL256491A (en) Pharmaceutical formulations
GB201517263D0 (en) Therapeutic agents
EP3302439A4 (en) Therapeutic composition
GB201509885D0 (en) Therapeutic agents
GB201516411D0 (en) Pharmaceutical compound
ZA201707094B (en) Pharmaceutical formulations
GB201509888D0 (en) Therapeutic agents
EP3355888B8 (en) Hemi-synthetic trilobine analogs for use as a drug
GB201513299D0 (en) Therapeutic agents
PT3288967T (pt) Composto farmacêutico
EP3226882A4 (en) Therapeutic compositions
GB201516153D0 (en) Chewable medicament
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
GB201505393D0 (en) Antimicrobal peptide formulations
EP3381995A4 (en) Oil-gelling agent
SG11201708817XA (en) Pharmaceutical compound
HK1253843A1 (zh) 治疗性组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)